Table 1.
The inhibitory activities (IC50) of ursolic acid (UA 1) and derivatives 2–17 in the lung cancer cell lines.
| Cell line(a)/IC50
|
|||
|---|---|---|---|
| Compound | H460 | H322 | H460 LKB1+/+ |
| UA 1 | 14.8±0.6 | 15.3±2.8 | 21.1±1.6 |
| 2 | 19.3±2.6 | 14.3±2.7 | 18.7±3.7 |
| 3 | >50 | >50 | >50 |
| 4 | >25 | >25 | 13.5±0.5 |
| 5 | ND | ND | ND |
| 6 | >50 | >50 | >50 |
| 7 | 23.0±2.3 | 24.1±2.5 | 21.8±3.2 |
| 8 | >17 | >17 | >17 |
| 9 | >50 | >50 | >50 |
| 10 | >50 | >50 | >50 |
| 11 | >50 | >50 | >50 |
| 12 | >50 | >50 | >50 |
| 13 | >50 | >50 | >50 |
| 14 | >50 | >50 | >50 |
| 15 | 4.5±0.4 | 6.8±1.5 | 6.7±0.5 |
| 16 | 5.3±0.3 | 7.3±1.0 | 7.8±1.1 |
| 17 | 2.6±0.9 | 3.3±0.9 | 4.4±0.6 |
(a)
Lung cancer cell lines were treated with various concentrations of test compounds for 72h. The inhibitory activities were determined using CellTiter-Blue®. IC50 was calculated from the results, and data are presented as means ± SD (standard deviation) of three independent experiments.